You just read:

Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

News provided by

Valeant Pharmaceuticals International, Inc.

Nov 02, 2017, 16:05 ET